EUVIMEDEUVIMED entdecken
Open Access

Tumor Hypoxia on 18 F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma

Chengcheng Gui, Rick Wray, Heiko Schöder, Joseph O Deasy, Milan Grkovski, John L Humm, Richard J Wong, Eric J Sherman, Nadeem Riaz, Nancy Y Lee

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.36407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Chengcheng Gui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Misonidazole, Tumor Hypoxia, Squamous Cell Carcinoma of Head and Neck, Positron-Emission Tomography. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Given high rates of locoregional control after definitive management of head and neck squamous cell carcinoma (HNSCC), better methods are needed to project distant metastasis (DM) risk. Tumor hypoxia on 18 F-fluoromisonidazole (FMISO) positron emission tomography (PET) is associated with locoregional failure, but data demonstrating an association with DM are limited.

Objective

To determine whether tumor hypoxia on FMISO PET is associated with DM risk after chemoradiotherapy (CRT) for HNSCC. Design, Setting, and Participants This cohort study assessed patients with HNSCC enrolled in 2 prospective clinical trials at a single academic referral center from 2004 to 2021 in which participants received FMISO PET before and during CRT. Data analysis occurred from May 2023 to May 2024. Exposures FMISO PET scans before and 1 to 2 weeks after starting CRT were evaluated for tumor hypoxia by nuclear medicine physicians. Main Outcomes and Measures The primary outcome was DM, defined as biopsy-proven HNSCC outside the primary site and regional lymph nodes. Time to DM was modeled with competing risk regression, with death as a competing risk. Overall survival (OS) was assessed secondarily and modeled with Cox regression.

Results

Among 281 patients (median [range] age at CRT, 58.7 [25.5-85.6] years; 251 male [89.3%]) included in this study, 242 (86.1%) had oropharyngeal primary cancer, and 266 (94.7%) had human papillomavirus–positive disease. Of all patients, 217 (77.2%) had T stage 1 or 2, and 231 patients (82.2%) had N stage 2b or less. De-escalated 30 Gy CRT was delivered to 144 patients (51.2%), and the remainder received standard 70 Gy CRT. On FMISO PET examination, 73 patients (26.0%) had hypoxia-negative disease before CRT, 138 patients (49.1%) had hypoxia-positive disease before CRT and then hypoxia-negative disease during CRT, and 70 patients (24.9%) persistently had hypoxia-positive disease before and during CRT. At a median (IQR) 58 (46-91) months of follow-up, 12 DM events and 22 deaths were observed. Persistent intratreatment hypoxia was associated with increased DM risk (hazard ratio, 3.51; 95% CI, 1.05-11.79; P = .04) and worse OS (hazard ratio, 2.66; 95% CI, 1.14-6.19; P = .02). No patients with hypoxia-negative disease before CRT experienced DM. Conclusions and Relevance In this cohort study using pooled analysis of prospective nonrandomized clinical trials incorporating FMISO PET in the definitive management of HNSCC, persistent intratreatment hypoxia was associated with increased risk of DM and worse OS. Conversely, all patients with hypoxia-negative disease before treatment remained free of DM. These findings suggest that pretreatment and intratreatment FMISO PET results may serve as biomarkers for DM risk and aid in identifying candidates for escalated therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MisonidazoleTumor HypoxiaSquamous Cell Carcinoma of Head and NeckPositron-Emission TomographyHead and Neck NeoplasmsHumansMaleMiddle AgedFemaleAgedProspective StudiesChemoradiotherapyCohort StudiesNeoplasm Metastasis

Substanzen

Misonidazolefluoromisonidazole

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Gui, C., Wray, R., Schöder, H., Deasy, J. O., Grkovski, M., Humm, J. L., Wong, R. J., Sherman, E. J., Riaz, N., & Lee, N. Y. (2024). Tumor Hypoxia on 18 F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.36407

Vancouver

Gui C, Wray R, Schöder H, Deasy JO, Grkovski M, Humm JL, et al. Tumor Hypoxia on 18 F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.36407

BibTeX
@article{Gui2024,
  author = {Gui, Chengcheng and Wray, Rick and Schöder, Heiko and Deasy, Joseph O and Grkovski, Milan and Humm, John L and Wong, Richard J and Sherman, Eric J and Riaz, Nadeem and Lee, Nancy Y},
  title = {Tumor Hypoxia on 18 F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.36407}
}
Kostenlos starten →